WHO (World Health Organization) Available
at: http://www.who.int/mediacentre/factsheets/fs297/en/ Accessed January
2007.
2.
Chabner BA, Allegra C.J.,
Curt
GA, Calabresi P., Antineoplastic
agents. Hardman
JG, Limbird LE, eds. Goodman, &
Gilman's The Pharmacological basis of therapeutics.
Ninth edn. New York, NY:
McGraw-Hill, 1996:
1233—87.
3.
ASHP (American Society of Health System
Pharmacists).Guidelines on handling
hazardous drugs. Am J Health Syst
Pharm2006; 63:
1172—93.
4.
OSHA (Occupational Safety and Health
Administration)Technical Manual, TED 1-0.15 A,
Section VI, Chapter 2, Jan 20, 1999.
Availableat:http://www.osha.gov/dts/osta/otm/otmvi/otmvi2.html#2 Accessed
January 2007.
5.
NIOSH Alert: preventing occupational
exposures to antineoplastic and other hazardous drugs in health care settings
2004. U.S. Department of Health and Human Services, Public
Health Service, Centers for Disease Control and Prevention, National Institute for
Occupational Safety and Health, DHHS (NIOSH) Publication No
2004—165.
6.
Falck K., Gröhn P.,
Sorsa
M., Vainio H., Heinonen E.,
Holsti
LRMutagenicity in urine of nurses handling
cytostatc drugs. Lancet1979;
1: 1250—51.
7.
Baker ES, Connor
THMonitoring occupational exposure to cancer
chemotherapy drugs. Am J Health System
Pharm1996; 53:
2713—23.
8.
Sorsa M., Anderson
D.Monitoring of occupational exposure to
cytostatic anticancer agents. Mutat
Res1996; 355:
253—61.
9.
Sessink Pjm, Bos
RPDrugs hazardous to healthcare workers:
evaluation of methods for monitoring occupational exposure to cytostatic
drugs. Drug Saf1999; 20:
347—59.
10.
Harrison BRRisks of handling
cytotoxic drugs. In: Perry MC., eds.. The chemotherapy
source book. Third edn, Philadelphia,
PA; Lippincott ,
Williams, & Wilkins,
2001.
11.
Selevan SG, Lindbohm M-L.,
Hornung
RW, Hemminki K.A study of
occupational exposure to antineoplastic drugs and fetal loss in nurses.
N Engl J Med1985; 313:
1173—78.
12.
Stücker I., Caliiard J-F.,
Collin
R., Gout M., Poyen D.,
Hémon,
D.Risk of spontaneous abortion among nurses
handling antineoplastic drugs. Scand J Work Environ
Health1990; 16:
102—107.
13.
Hemminki K. , Kyyrönen P.,
Lindbohm
M-L.Spontaneous abortions and malformations
in the offspring of nurses exposed to anesthetic gases, cytostatic drugs, and other
potential hazards in hospitals, based on registered information of outcome. J
EpidemolCommunity Health1985 ;
39: 141—47.
14.
Peelen S., Roeleveld N.,
Heederik
D., Kromhout H., de Kort
W.Toxic effects on reproduction in hospital
personnel (in Dutch). Reproductie-toxische effecten bij ziekenhuispersonel.
Netherlands; Elsivier ,
1999.
15.
Valanis B., Vollmer WM,
Steele
P.Occupational exposure to antineoplastic
agents: Self-reported miscarriages and stillbirths among nurses and
pharmacists. J Occup Environ Med1999;
41: 632—38.
16.
NIH (National Institutes of
Health).Recommendations for the safe use of
handling of cytotoxic drugs. Available at:
http://www.nih.gov/od/ors/ds/pubs/cytohttp://dohs.ors.od.nih.gov/pdf/Recommendations_for_the_Safe_Use_of_Handling_of_Cytotoxic_Drugs.pdf
Accessed January 2007.
17.
NSCCE (National Study Commission on Cytotoxic
Exposure).Recommendations for handling cytotoxic
agents . Sept, 1987.
18.
AMA (American Medical Association) Council on Scientific
Affairs.Guidelines for handling parenteral
antineoplastic agents.
JAMA1985;253:
1590—92.
19.
COSA (Clinical Oncology Society of
Australia).Guidelines for safe handling of
antineoplastic agents. Med J
Aust1983;1:426—28.
20.
Colls BMCytotoxic
chemotherapy: A potential hazard to patients and hospital
personnel?N Z Med J1987;
100: 149—50.
21.
CSHP (Canadian Society of Hospital
Pharmacists).Guidelines for the handling and
disposal of hazardous pharmaceuticals (Including cytotoxic drugs),
Ottawa, Canada, 1993.
22.
SHPA (Society of Hospital Pharmacists in Australia) Committee of
Speciality Practice in Oncology (Davis J.,
Harsley
S., Kirsa S., McLauchlan R.,
Ng
L-L., Ooi S-C., Stefanou A.)
SHPA Standards of practice for the safe handling of cytotoxic drugs in
pharmacyJ Pharm Pract
Res2005;35:44—52.
23.
DGOP (Deutsche Gesellschaft fur Onkologische
Pharmazie).Quality Standard for the Oncology
Pharmacy Practice Service (QuapoS). 2003. Available in English at:
http://www.esop.li/countries/uk/quapos-2003-en.pdf Accessed February
2007.
24.
DGOP (Deutsche Gesellschaft fur Onkologische Pharmazie)/ESOP (European
Society of Oncology Practice).2nd
Polish—German annual conference for oncology pharmacy ``Therapy for
practice."' June 3—4
Franfort/Oder-S_ubice .
2005.
25.
NKI-AVL (Netherlands Cancer Institute — Antoni van Leeuwenhoek
Hospital).Kwaliteitshandboek Cytostatica
. 2004.
Connor TH, Shults M.,
Fraser
MPDetermination of the vaporization of
solutions of mutagenic antineoplastic agents at 23° and 37°C using a desiccator
technique. Mutat Res2000;
470: 85—92.
28.
Kiffmeyer TK, Kube C.,
Opiolka
S., Schmidt KG, Schöppe G.,
Sessink
Pjm.Vapor pressures, evaporation behaviour
and airborne concentrations of hazardous drugs: implications for occupational
safety. Pharmeaceut J2002;
268: 331—37.
29.
Sessink Pjm, Boer KA,
Scheefhals
AP, Anzion RB, Bos
RPOccupational exposure to antineoplastic
agents at several departments in a hospital: Environmental contamination and excretion
of cyclophosphamide and ifosfamide in urine of exposed workers.
Int Arch Occup Environ Health1992; 64:
105—12.
30.
Ros Jjw, Simons KA,
Verzijl
JM, de Bijl GA, Pelders
MGPractical applications of a validated
method of analysis for the detection of traces of cyclophosphamide on injection bottles
and at oncological outpatient center.
Ziekenhuisfarmacie1997; 13:
168—71.
31.
Hepp R., Gentschew
G.External contamination of commercially
available cytotoxic drugs.
Krankenhauspharmazie1998; 19:
22—27.
32.
Delporte JP , Chenoix P.,
Hubert
Ph.Chemical contamination of the primary
packaging of 5-fluorouracil RTU solutions commercially available on the Belgian
market . EHP1999; 5:
119—21.
33.
Nygren O., Gustavsson B.,
Ström
L., Friberg A.Cisplatin
contamination on the outside of drug vials. Ann Occup
Hyg2002; 46:
555—57.
Connor TH, Sessink Pjm,
Harrison
BR, et al. Surface contamination of
chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three
studies. Am J Health Syst Pharm2005;
62: 475—484.
36.
Sessink Pjm , Anzion RB,
van der Broek
Phh, Bos RPDetection of
contamination with antineoplastic agents in a hospital pharmacy
department. Pharm Weekbl [Sci]1992;
14: 16—22.
37.
McDevitt JJ , Lees Psj,
McDiarmid
MAExposure of hospital pharmacists and
nurses to antineoplastic agents. J Occup
Med1993 ; 35:
57—60.
38.
Pethran A., Hauff K.,
Hessel
H., Grimm C-H.Biological,
cytogenetic, and ambient monitoring of exposure to antineoplastic drugs.
J Oncol Pharm Pract1998; 4:
57.
39.
Minoia C., Turci R.,
Sottani
C., et al. Application of high performance
liquid chromatography/tandem mass spectrometry in the environmental and biological
monitoring of healthcare personnel occupationally exposed to cyclophosphamide and
ifosfamide. Rapid Commun Mass
Spectrom1998; 12:
1485—93.
40.
Rubino FM, Floridia L.,
Pietropaolo
AM, Tavazzani M., Colombi
A.Measurement of surface contamination by
certain antineoplastic drugs using high-performance liquid chromatography: applications
in occupational hygiene investigations in hospital environments.
Med Lav1999; 90:
572—83.
41.
Connor TH, Anderson RW,
Sessink
PJ, Broadfield L., Power
LASurface contamination with antineoplastic
agents in six cancer treatment centers in Canada and the United States.
Am J Health Syst Pharm1999; 56:
1427—32.
42.
Micoli G., Turci R.,
Arpellini
M., Minoia C.Determination of
5-fluorouracil in environmental samples by solid-phase extraction and high-performance
liquid chromatography with ultraviolet detection. J Chromatogr B
Biomed Sci Appl2001; 750:
25—32.
43.
Vandenbroucke J., Robays
H.How to protect environment and employees
against cytotoxic agents, the UZ Ghent experience. J Oncol Pharm
Pract2001; 6:
146—52.
44.
Connor TH, Anderson RW,
Sessink
PJ, Spivey SMEffectiveness of a
closed-system device in containing surface contamination with cyclophosphamide and
ifosfamide in an i.v. admixture area. Am J Health Syst
Pharm2002; 59:
68—72.
45.
Schmaus G., Schierl R.,
Funck
S.Monitoring surface contamination by
antineoplastic drugs using gas chromatography-mass spectrometry and
voltammetry. Am J Health Syst Pharm2002;
59: 956—61.
46.
Wick C., Slawson MH,
Jorgenson JA; Tyler
LSUsing a closed-system protective device
to reduce personnel exposure to antineoplastic agents. Am J
Health Syst Pharm2003; 60:
2314—20.
47.
Zeedijk M., Greijdanus B.,
Steenstra
FB, Uges Dra.Monitoring exposure
of cytotoxics on the hospital ward: measuring surface contamination of four different
cytostatic drugs from one wipe sample. EJHP-S (Science)
2005; 11:
18—22.
48.
Crauste-Manciet S., Sessink Pjm,
Ferrari
S., Jomier J-Y., Brossard
D.Environmental contamination with cytotoxic
drugs in healthcare using positive air pressure isolators. Ann
Occup Hygiene2005; 49:
619—28.
